Filtered By:
Drug: Humira

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 26 results found since Jan 2013.

A case of “smoldering” immune‐mediated thrombotic thrombocytopenic purpura manifesting as recurrent cardioembolic stroke
We report an atypical manifestation of immune-mediated thrombotic thrombocytopenic purpura (TTP) that we hypothesize represents a longstanding, or “smoldering,” process. As typified by this case, the prompt recognition and treatment for immune-mediated TTP are often confounded by clinical comorbidities. Thus, TTP should be considered in cases of unremitting thrombocytopenia of unknown origin in patients with stroke or other thrombosis. AbstractPrompt recognition and treatment for thrombotic thrombocytopenic purpura (TTP) are critical to prevent the irreversible manifestations of this rare and quickly fatal hematologic ...
Source: Clinical Case Reports - October 12, 2021 Category: General Medicine Authors: Mark E. Pepin, Eyad Saca, Soo Y. Kwon, Jori May Tags: CASE REPORT Source Type: research

Brainstem Infarction in Immunodeficiency Identified as Adenosine Deaminase 2 Deficiency: Case Report
ConclusionWe present the case of a young adult with diagnosis of DADA2 as a cause for recurrent strokes due to vasculitis. This stroke etiology is rare but should be considered as a cause of recurrent stroke of unknown origin in young patients to avoid a disabling disease course by disease-specific treatment options.
Source: Journal of Clinical Immunology - June 12, 2023 Category: Allergy & Immunology Source Type: research

Effects of the Tumor Necrosis Factor-{alpha} Antagonist Adalimumab on Arterial Inflammation Assessed by Positron Emission Tomography in Patients With Psoriasis: Results of a Randomized Controlled Trial Original Articles
Conclusions— The study did not meet its primary end point because the change in target:background ratio in patients randomized to adalimumab was not different from controls. Although adalimumab may reduce vascular inflammation in patients with moderate to severe psoriasis, this effect is not large enough to be demonstrated in a study with a small sample size. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NTC00940862.
Source: Circulation: Cardiovascular Imaging - January 15, 2013 Category: Radiology Authors: Bissonnette, R., Tardif, J.-C., Harel, F., Pressacco, J., Bolduc, C., Guertin, M.-C. Tags: Lipids, Cardiovascular Pharmacology, Risk Factors, Imaging, CT and MRI, Nuclear cardiology and PET Original Articles Source Type: research

Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis.
CONCLUSION: Based on data accumulated to date in PSOLAR, treatment with biologics did not have an impact on the risk of MACE in patients with moderate-to-severe psoriasis. <p><em>J Drugs Dermatol. 2017;16 (10):1002-1013.</em></p>. PMID: 29036254 [PubMed - in process]
Source: Journal of Drugs in Dermatology - October 18, 2017 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Indolent nonendemic central nervous system histoplasmosis presenting as an isolated intramedullary enhancing spinal cord lesion
CONCLUSION: Disseminated histoplasmosis should be considered in granulomatous disease, even if the patient resides in a nonendemic region. Furthermore, clinicians should be mindful that CNS histoplasmosis may present in an atypical fashion.PMID:34513158 | PMC:PMC8422457 | DOI:10.25259/SNI_345_2021
Source: Surgical Neurology International - September 13, 2021 Category: Neurosurgery Authors: Matthew J Recker Steven B Housley Lindsay J Lipinski Source Type: research